Journey Medical Corporation

$7.12

$-0.33 (-4.43%)

Jan 5, 2026

Price History (1Y)

Analysis

Journey Medical Corporation operates in the healthcare sector, specifically within the drug manufacturers - specialty & generic industry. The company has a market capitalization of $193.21M and generates revenue of approximately $59.40M on an annualized basis. Journey Medical Corporation employs 41 individuals. The company's financial performance indicates a challenging period. Net income for the trailing twelve months (TTM) stands at -$8,663,000, while EBITDA is -$1,321,000. The operating margin and profit margin are -8.7% and -14.6%, respectively. Journey Medical Corporation has a significant amount of debt, totaling $25.30M, and relatively low cash reserves of $24.95M. The current ratio is 1.42. The valuation metrics suggest that the company's stock price may be under pressure. The forward P/E ratio stands at -118.67, indicating a potential decline in earnings expectations. The price to book value is 7.25, and the EV/EBITDA ratio is -153.31. Revenue growth for the year-over-year (YoY) period has been positive, with an increase of 20.5%. However, earnings growth is not available due to a negative number.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Journey Medical Corporation

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Visit website →

Key Statistics

Market Cap
$193.21M
P/E Ratio
N/A
52-Week High
$9.40
52-Week Low
$3.54
Avg Volume
180.96K
Beta
0.82

Company Info

Exchange
NCM
Country
United States
Employees
41